Clinical Trial Update: Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 study of oxaliplatin, ifosfamide, and etoposide in young patients with recurrent or refractory solid tumors or lymphomas; the trial has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angioimmunoblastic T-cell Lymphoma
• B-cell Childhood Acute Lymphoblastic Leukemia
• Childhood Burkitt Lymphoma
• Childhood Diffuse Large Cell Lymphoma
• Childhood Hodgkin Lymphoma
• Childhood Lymphoblastic Lymphoma
• Chronic Lymphocytic Leukemia
• Small Intestine Lymphoma

Drugs mentioned

• Etoposide (Etoposide)
• IFOSFAMIDE (IFOSFAMIDE)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Angioimmunoblastic T-cell Lymphoma, B-cell Childhood Acute Lymphoblastic Leukemia | Phase 1 | Status: TERMINATED